Plain language summary
Mitochondria are the main generators of energy in cells. Dysfunction of mitochondria has been seen in people with chronic diseases and this may be due to an increase in inflammation controlled by the gut microbiota. Several dietary strategies have been thought to aid mitochondrial function including intermittent fasting (IF), ketogenic diet (KD), and calorie restriction (CR). This randomised control trial of 44 individuals with obesity aimed to determine the effects of IF (16:8 pattern), KD (15-25% protein, 5-10% carbohydrate, 70-80% fat), and CR (25-35% protein, 45-55% carbohydrates, 20-30% fat) on mitochondrial function in cells responsible for inflammation and on gut microbiota. The results showed that after one month IF, KD, and CR improved mitochondrial function and energy production, decreased body weight and belly fat and increased gut microbiota diversity and changed several different species. Gut microbiota were shown to be modulating the alterations in mitochondrial function through the generation of inflammatory molecules. It was concluded that changes in diet altered the gut microbiota, which had favourable effects on inflammation and mitochondrial function. This study could be used by healthcare professionals to understand that in the short term IF, CR, and KD can help weight loss in individuals with obesity and this may be due to favourable effects on the gut microbiota.
Abstract
BACKGROUND Mitochondrial dysfunction occurs in monocytes during obesity and contributes to a low-grade inflammatory state; therefore, maintaining good mitochondrial conditions is a key aspect of maintaining health. Dietary interventions are primary strategies for treating obesity, but little is known about their impact on monocyte bioenergetics. Thus, the aim of this study was to evaluate the effects of calorie restriction (CR), intermittent fasting (IF), a ketogenic diet (KD), and an ad libitum habitual diet (AL) on mitochondrial function in monocytes and its modulation by the gut microbiota. METHODS AND FINDINGS A randomized controlled clinical trial was conducted in which individuals with obesity were assigned to one of the 4 groups for 1 month. Subsequently, the subjects received rifaximin and continued with the assigned diet for another month. The oxygen consumption rate (OCR) was evaluated in isolated monocytes, as was the gut microbiota composition in feces and anthropometric and biochemical parameters. Forty-four subjects completed the study, and those who underwent CR, IF and KD interventions had an increase in the maximal respiration OCR (p = 0.025, n2p = 0.159 [0.05, 0.27] 95% confidence interval) in monocytes compared to that in the AL group. The improvement in mitochondrial function was associated with a decrease in monocyte dependence on glycolysis after the IF and KD interventions. Together, diet and rifaximin increased the gut microbiota diversity in the IF and KD groups (p = 0.0001), enriched the abundance of Phascolarctobacterium faecium (p = 0.019) in the CR group and Ruminococcus bromii (p = 0.020) in the CR and KD groups, and reduced the abundance of lipopolysaccharide (LPS)-producing bacteria after CR, IF and KD interventions compared to the AL group at the end of the study according to ANCOVA with covariate adjustment. Spearman's correlation between the variables measured highlighted LPS as a potential modulator of the observed effects. In line with this findings, serum LPS and intracellular signaling in monocytes decreased with the three interventions (CR, p = 0.002; IF, p = 0.001; and KD, p = 0.001) compared to those in the AL group at the end of the study. CONCLUSIONS We conclude that these dietary interventions positively regulate mitochondrial bioenergetic health and improve the metabolic profile of monocytes in individuals with obesity via modulation of the gut microbiota. Moreover, the evaluation of mitochondrial function in monocytes could be used as an indicator of metabolic and inflammatory status, with potential applications in future clinical trials. TRIAL REGISTRATION This trial was registered with ClinicalTrials.gov (NCT05200468).
Methodological quality
Jadad score
:
3
Allocation concealment
:
Yes